***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Histamine Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | -0.574 | 0.000 | . | 0.1057 | 0.27 | 0.00 | 0.00 | 0.00 | 0.9208 |
|  | [B] 0.10% ZPT | 86 | -0.580 | 0.000 | . | 0.1057 | 0.26 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | -0.672 | -0.097 | 0.1611 | 0.0686 | 0.21 | -20.0 | -31.7 | -6.34 | 0.2477 |
|  | [B] 0.10% ZPT | 85 | -0.744 | -0.169 | 0.0159 | 0.0686 | 0.18 | -32.2 | -42.1 | -20.6 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | -0.598 | 0.000 | . | 0.1064 | 0.25 | 0.00 | 0.00 | 0.00 | 0.2364 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | -0.688 | 0.000 | . | 0.1064 | 0.21 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | -0.824 | -0.192 | 0.0113 | 0.0739 | 0.15 | -35.7 | -45.7 | -23.7 | 0.8043 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | -0.843 | -0.211 | 0.0055 | 0.0739 | 0.14 | -38.5 | -48.1 | -27.0 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log IL1raIL1a Ratio***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.214 | 0.000 | . | 0.0681 | 1.64 | 0.00 | 0.00 | 0.00 | 0.7802 |
|  | [B] 0.10% ZPT | 86 | 0.202 | 0.000 | . | 0.0681 | 1.59 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | -0.010 | -0.228 | <.0001 | 0.0338 | 0.98 | -40.9 | -45.3 | -36.1 | 0.2490 |
|  | [B] 0.10% ZPT | 85 | 0.039 | -0.179 | <.0001 | 0.0338 | 1.09 | -33.8 | -38.8 | -28.4 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.200 | 0.000 | . | 0.0791 | 1.58 | 0.00 | 0.00 | 0.00 | 0.3189 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.246 | 0.000 | . | 0.0791 | 1.76 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 0.055 | -0.149 | 0.0005 | 0.0408 | 1.13 | -29.0 | -35.3 | -22.0 | 0.3141 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 0.001 | -0.202 | <.0001 | 0.0408 | 1.00 | -37.3 | -42.9 | -31.1 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log IL1ra Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.113 | 0.000 | . | 0.0434 | 12.98 | 0.00 | 0.00 | 0.00 | 0.5562 |
|  | [B] 0.10% ZPT | 86 | 1.094 | 0.000 | . | 0.0434 | 12.42 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 0.879 | -0.228 | <.0001 | 0.0332 | 7.56 | -40.8 | -45.2 | -36.1 | 0.3997 |
|  | [B] 0.10% ZPT | 85 | 0.912 | -0.194 | <.0001 | 0.0332 | 8.17 | -36.1 | -40.8 | -31.0 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.084 | 0.000 | . | 0.0444 | 12.14 | 0.00 | 0.00 | 0.00 | 0.2957 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.118 | 0.000 | . | 0.0444 | 13.12 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 0.929 | -0.161 | <.0001 | 0.0356 | 8.49 | -31.0 | -36.5 | -25.2 | 0.2985 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 0.885 | -0.205 | <.0001 | 0.0356 | 7.67 | -37.6 | -42.5 | -32.3 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log IL1a Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.900 | 0.000 | . | 0.0373 | 7.94 | 0.00 | 0.00 | 0.00 | 0.7491 |
|  | [B] 0.10% ZPT | 86 | 0.892 | 0.000 | . | 0.0373 | 7.81 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 0.888 | 0.000 | 0.9924 | 0.0215 | 7.73 | 0.05 | -4.78 | 5.12 | 0.5917 |
|  | [B] 0.10% ZPT | 85 | 0.873 | -0.015 | 0.4785 | 0.0215 | 7.46 | -3.46 | -8.12 | 1.43 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.884 | 0.000 | . | 0.0463 | 7.66 | 0.00 | 0.00 | 0.00 | 0.6611 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.872 | 0.000 | . | 0.0463 | 7.45 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 0.878 | -0.009 | 0.7222 | 0.0247 | 7.55 | -2.01 | -7.43 | 3.73 | 0.9408 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 0.880 | -0.007 | 0.7895 | 0.0247 | 7.58 | -1.51 | -6.96 | 4.26 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Protein Histamine***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.308 | 0.000 | . | 0.0238 | 20.31 | 0.00 | 0.00 | 0.00 | 0.7864 |
|  | [B] 0.10% ZPT | 86 | 1.314 | 0.000 | . | 0.0238 | 20.62 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 1.152 | -0.162 | <.0001 | 0.0206 | 14.18 | -31.1 | -34.3 | -27.8 | 0.7426 |
|  | [B] 0.10% ZPT | 85 | 1.159 | -0.155 | <.0001 | 0.0206 | 14.41 | -30.1 | -33.3 | -26.6 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.321 | 0.000 | . | 0.0264 | 20.96 | 0.00 | 0.00 | 0.00 | 0.3804 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.342 | 0.000 | . | 0.0264 | 21.97 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 1.174 | -0.155 | <.0001 | 0.0225 | 14.94 | -30.0 | -33.5 | -26.2 | 0.6793 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 1.164 | -0.165 | <.0001 | 0.0225 | 14.60 | -31.5 | -35.0 | -27.9 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Protein Cytokine***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.988 | 0.000 | . | 0.0294 | 9.72 | 0.00 | 0.00 | 0.00 | 0.9484 |
|  | [B] 0.10% ZPT | 86 | 0.986 | 0.000 | . | 0.0294 | 9.68 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 0.731 | -0.259 | <.0001 | 0.0262 | 5.38 | -44.9 | -48.2 | -41.5 | 0.0481 |
|  | [B] 0.10% ZPT | 85 | 0.782 | -0.208 | <.0001 | 0.0262 | 6.05 | -38.0 | -41.6 | -34.2 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.953 | 0.000 | . | 0.0354 | 8.97 | 0.00 | 0.00 | 0.00 | 0.4492 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.974 | 0.000 | . | 0.0354 | 9.42 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 0.775 | -0.185 | <.0001 | 0.0272 | 5.96 | -34.7 | -38.7 | -30.5 | 0.2202 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 0.739 | -0.221 | <.0001 | 0.0272 | 5.48 | -39.9 | -43.6 | -36.0 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Histamine***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.734 | 0.000 | . | 0.1099 | 5.42 | 0.00 | 0.00 | 0.00 | 0.9990 |
|  | [B] 0.10% ZPT | 86 | 0.734 | 0.000 | . | 0.1099 | 5.42 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 0.481 | -0.258 | 0.0015 | 0.0787 | 3.03 | -44.8 | -53.9 | -33.8 | 0.3284 |
|  | [B] 0.10% ZPT | 85 | 0.413 | -0.326 | <.0001 | 0.0787 | 2.59 | -52.7 | -60.6 | -43.4 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.724 | 0.000 | . | 0.1120 | 5.29 | 0.00 | 0.00 | 0.00 | 0.3727 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.654 | 0.000 | . | 0.1120 | 4.51 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 0.357 | -0.340 | 0.0001 | 0.0841 | 2.27 | -54.3 | -62.3 | -44.5 | 0.6050 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 0.315 | -0.382 | <.0001 | 0.0841 | 2.06 | -58.5 | -65.8 | -49.6 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log IL1ra***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 2.101 | 0.000 | . | 0.0591 | 126.17 | 0.00 | 0.00 | 0.00 | 0.6488 |
|  | [B] 0.10% ZPT | 86 | 2.080 | 0.000 | . | 0.0591 | 120.20 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 1.611 | -0.486 | <.0001 | 0.0486 | 40.81 | -67.3 | -70.8 | -63.4 | 0.1012 |
|  | [B] 0.10% ZPT | 85 | 1.693 | -0.404 | <.0001 | 0.0486 | 49.31 | -60.5 | -64.7 | -55.8 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 2.037 | 0.000 | . | 0.0654 | 108.89 | 0.00 | 0.00 | 0.00 | 0.2398 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 2.092 | 0.000 | . | 0.0654 | 123.56 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 1.702 | -0.348 | <.0001 | 0.0543 | 50.39 | -55.1 | -60.4 | -49.2 | 0.1957 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 1.626 | -0.425 | <.0001 | 0.0543 | 42.23 | -62.4 | -66.8 | -57.4 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log IL1a***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.887 | 0.000 | . | 0.0398 | 77.16 | 0.00 | 0.00 | 0.00 | 0.7154 |
|  | [B] 0.10% ZPT | 86 | 1.878 | 0.000 | . | 0.0398 | 75.55 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 1.619 | -0.259 | <.0001 | 0.0327 | 41.59 | -44.9 | -48.9 | -40.6 | 0.2916 |
|  | [B] 0.10% ZPT | 85 | 1.655 | -0.223 | <.0001 | 0.0327 | 45.19 | -40.1 | -44.5 | -35.5 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.837 | 0.000 | . | 0.0498 | 68.73 | 0.00 | 0.00 | 0.00 | 0.7537 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.846 | 0.000 | . | 0.0498 | 70.19 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 1.656 | -0.191 | <.0001 | 0.0389 | 45.29 | -35.6 | -41.1 | -29.5 | 0.2965 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 1.616 | -0.231 | <.0001 | 0.0389 | 41.29 | -41.3 | -46.3 | -35.7 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Hsa Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.754 | 0.000 | . | 0.0768 | 5.67 | 0.00 | 0.00 | 0.00 | 0.6871 |
|  | [B] 0.10% ZPT | 86 | 0.733 | 0.000 | . | 0.0768 | 5.41 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 0.253 | -0.497 | <.0001 | 0.0679 | 1.79 | -68.2 | -72.8 | -62.8 | 0.2577 |
|  | [B] 0.10% ZPT | 85 | 0.320 | -0.430 | <.0001 | 0.0679 | 2.09 | -62.9 | -68.3 | -56.6 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.738 | 0.000 | . | 0.0683 | 5.47 | 0.00 | 0.00 | 0.00 | 0.4100 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.695 | 0.000 | . | 0.0683 | 4.96 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 0.310 | -0.391 | <.0001 | 0.0578 | 2.04 | -59.4 | -64.4 | -53.6 | 0.0323 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 0.453 | -0.248 | <.0001 | 0.0578 | 2.84 | -43.5 | -50.5 | -35.4 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Involucrin Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | -1.585 | 0.000 | . | 0.0370 | 0.03 | 0.00 | 0.00 | 0.00 | 0.1971 |
|  | [B] 0.10% ZPT | 86 | -1.540 | 0.000 | . | 0.0370 | 0.03 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | -1.678 | -0.114 | 0.0045 | 0.0390 | 0.02 | -23.1 | -29.7 | -15.8 | 0.0956 |
|  | [B] 0.10% ZPT | 85 | -1.614 | -0.050 | 0.2068 | 0.0390 | 0.02 | -10.8 | -18.4 | -2.41 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | -1.513 | 0.000 | . | 0.0427 | 0.03 | 0.00 | 0.00 | 0.00 | 0.2712 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | -1.555 | 0.000 | . | 0.0427 | 0.03 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | -1.605 | -0.057 | 0.1593 | 0.0404 | 0.02 | -12.4 | -20.2 | -3.84 | 0.4065 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | -1.565 | -0.017 | 0.6777 | 0.0404 | 0.03 | -3.81 | -12.4 | 5.57 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Keratins11011 Normalized***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 0.722 | 0.000 | . | 0.0712 | 5.27 | 0.00 | 0.00 | 0.00 | 0.8236 |
|  | [B] 0.10% ZPT | 86 | 0.708 | 0.000 | . | 0.0712 | 5.11 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 1.060 | 0.350 | <.0001 | 0.0426 | 11.47 | 123.8 | 102.9 | 146.8 | 0.4235 |
|  | [B] 0.10% ZPT | 85 | 1.024 | 0.314 | <.0001 | 0.0426 | 10.57 | 106.1 | 86.84 | 127.3 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 0.768 | 0.000 | . | 0.0594 | 5.86 | 0.00 | 0.00 | 0.00 | 0.5861 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 0.736 | 0.000 | . | 0.0594 | 5.44 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 1.012 | 0.251 | <.0001 | 0.0360 | 10.29 | 78.22 | 64.05 | 93.62 | 0.5935 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 1.034 | 0.273 | <.0001 | 0.0360 | 10.82 | 87.52 | 72.61 | 103.7 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Protein SkinMap***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.148 | 0.000 | . | 0.0340 | 14.07 | 0.00 | 0.00 | 0.00 | 0.7299 |
|  | [B] 0.10% ZPT | 86 | 1.138 | 0.000 | . | 0.0340 | 13.73 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 0.754 | -0.388 | <.0001 | 0.0403 | 5.68 | -59.1 | -62.7 | -55.1 | 0.1880 |
|  | [B] 0.10% ZPT | 85 | 0.812 | -0.331 | <.0001 | 0.0403 | 6.48 | -53.3 | -57.5 | -48.8 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.127 | 0.000 | . | 0.0381 | 13.41 | 0.00 | 0.00 | 0.00 | 0.7466 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.118 | 0.000 | . | 0.0381 | 13.11 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 0.795 | -0.326 | <.0001 | 0.0420 | 6.24 | -52.7 | -57.1 | -47.9 | 0.2157 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 0.740 | -0.381 | <.0001 | 0.0420 | 5.49 | -58.4 | -62.2 | -54.1 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Hsa***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.902 | 0.000 | . | 0.0887 | 79.79 | 0.00 | 0.00 | 0.00 | 0.6195 |
|  | [B] 0.10% ZPT | 86 | 1.871 | 0.000 | . | 0.0887 | 74.25 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 1.008 | -0.885 | <.0001 | 0.0789 | 10.18 | -87.0 | -89.1 | -84.4 | 0.0726 |
|  | [B] 0.10% ZPT | 85 | 1.130 | -0.762 | <.0001 | 0.0789 | 13.50 | -82.7 | -85.6 | -79.3 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.865 | 0.000 | . | 0.0862 | 73.29 | 0.00 | 0.00 | 0.00 | 0.3990 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.813 | 0.000 | . | 0.0862 | 64.97 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 1.101 | -0.720 | <.0001 | 0.0728 | 12.62 | -81.0 | -83.9 | -77.5 | 0.1870 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 1.196 | -0.625 | <.0001 | 0.0728 | 15.72 | -76.3 | -79.9 | -71.9 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Involucrin***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | -0.437 | 0.000 | . | 0.0526 | 0.37 | 0.00 | 0.00 | 0.00 | 0.5035 |
|  | [B] 0.10% ZPT | 86 | -0.402 | 0.000 | . | 0.0526 | 0.40 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | -0.928 | -0.506 | <.0001 | 0.0475 | 0.12 | -68.8 | -72.1 | -65.2 | 0.0080 |
|  | [B] 0.10% ZPT | 85 | -0.798 | -0.377 | <.0001 | 0.0475 | 0.16 | -58.0 | -62.3 | -53.1 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | -0.386 | 0.000 | . | 0.0556 | 0.41 | 0.00 | 0.00 | 0.00 | 0.2586 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | -0.437 | 0.000 | . | 0.0556 | 0.37 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | -0.809 | -0.382 | <.0001 | 0.0514 | 0.16 | -58.5 | -63.1 | -53.3 | 0.7731 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | -0.826 | -0.399 | <.0001 | 0.0514 | 0.15 | -60.1 | -64.5 | -55.0 | . |
|  | | | | | | | | | | | |

***CRB 11-01-004 SSS 19 Treatment Phase***

***Analysis for Log Keratins11011***

| **Visit** | **Trt** | **Sample Size** | **Adjusted Mean** | **Change from Baseline Adjusted Mean** | **Change from Baseline P-Value** | **Standard Error** | **Geometric Mean** | **% Change From Baseline** | **% Change - SE From Baseline** | **% Change + SE From Baseline** | **P-Value (Two-Sided)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | [A] 0.03% ZPT | 86 | 1.870 | 0.000 | . | 0.0590 | 74.18 | 0.00 | 0.00 | 0.00 | 0.6185 |
|  | [B] 0.10% ZPT | 86 | 1.846 | 0.000 | . | 0.0590 | 70.17 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [A] 0.03% ZPT | 85 | 1.812 | -0.040 | 0.2027 | 0.0314 | 64.90 | -8.88 | -15.2 | -2.04 | 0.4625 |
|  | [B] 0.10% ZPT | 85 | 1.837 | -0.015 | 0.6316 | 0.0314 | 68.78 | -3.42 | -10.2 | 3.82 | . |
|  | | | | | | | | | | | |
| Baseline | [C] 0.03% ZPT | 86 | 1.895 | 0.000 | . | 0.0504 | 78.53 | 0.00 | 0.00 | 0.00 | 0.3748 |
|  | [D] 0.03% ZPT + 0.06% ZC | 86 | 1.854 | 0.000 | . | 0.0504 | 71.38 | 0.00 | 0.00 | 0.00 | . |
| Week 2 | [C] 0.03% ZPT | 84 | 1.811 | -0.070 | 0.0406 | 0.0338 | 64.77 | -14.9 | -21.3 | -8.06 | 0.1437 |
|  | [D] 0.03% ZPT + 0.06% ZC | 84 | 1.770 | -0.112 | 0.0014 | 0.0338 | 58.85 | -22.7 | -28.5 | -16.5 | . |
|  | | | | | | | | | | | |